TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02431312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9112
Description: INO-9112 delivered by EP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9112
Description: INO-9112 delivered by EP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue Treatment
Description: Continued treatment with nucleos(t)ide analogue
Study: NCT04211350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightBalance Sleep Position Trainer (SPT)
Description: NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP)
Description: Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
Study: NCT01705080

Intervention type: DEVICE
Intervention: EnligHTN
Description: Renal artery ablation with EnligHTN system used for all groups

Intervention type: DEVICE
Intervention: EnligHTN
Description: Renal artery ablation with EnligHTN system used for all groups

Intervention type: DEVICE
Intervention: EnligHTN
Description: Renal artery ablation with EnligHTN system used for all groups
Study: NCT04360460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality + related functional translation into real-life
Description: The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality + non-related translation into real-life
Description: The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
Study: NCT04328909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Care
Description: Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Usual care - No E-Care app will be provided
Study: NCT04545450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride 5 mg/day
Description: Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
Study: NCT02972268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin 0.2mg + Placebo(Solifenacin)
Description: Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
Study: NCT01249950

Intervention type: OTHER
Intervention: feasibility
Description: feasibility
Study: NCT01828762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-TC+GM-CSF
Study: NCT04417738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral transcranial photobiomodulation, near infrared mode
Description: The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
Study: NCT01333813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B™ Kinder
Description: Intramuscular, single dose
Study: NCT01663051

Intervention type: DEVICE
Intervention: Zilver Vena Venous Stent
Description: Stenting iliofemoral venous outflow obstruction
Study: NCT05751954

Intervention type: RADIATION
Group type: OTHER
Intervention: Postero-anterior weight-bearing full-leg radiograph
Description: Full leg standing X ray of the involved lower extremity (postero-anterior direction)

Intervention type: DEVICE
Group type: OTHER
Intervention: Pedobarographic analysis
Description: Foot pressure analysis during gait on pedobarographic device
Study: NCT01208649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide
Description: Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
Study: NCT02240953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin + ASA 100 mg + PPI
Description: 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin + ASA 300 mg + PPI
Description: In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Observational Warfarin
Description: This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
Study: NCT04473599

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uniform random message delivery
Description: In this arm, the categories and timings of text-messages will be delivered to participants using a random schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement learning message delivery
Description: In this arm, the categories and timings of text-messages will be chosen by a reinforcement learning algorithm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood ratings only
Description: In this arm, participants will monitor their mood daily and receive feedback on that mood randomly
Study: NCT03112460

Intervention type: DEVICE
Intervention: cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
Description: cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
Study: NCT04224376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App based Serious Gaming with the Genu Sport knee trainer
Description: The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
Study: NCT04904198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management Intervention for non-cardiac chest pain
Description: Multicomponent eight-week care management intervention involving a consultation visit with a cardiologist and nurse. Recommendations from the consultation visit are conveyed to the primary care physician. Following the visit, the participant has eight weekly phone calls with a nurse to provide support, introduce therapeutic principals, and assess symptoms. The study nurse is supervised by a psychiatrist.
Study: NCT04441853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YouTube video
Description: Tutoral session on using YouTube personal stories on older people

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Tutorial session with same content without Youtube video
Study: NCT02734953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
Study: NCT02546921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT01167491

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Physiopathology Endpoint Classification
Description: Blood samples will be collected during a routine medical visit.
Study: NCT02186600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
Study: NCT04545450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
Study: NCT02585453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Gel
Description: Manufacturer: Laboratoires Thea, France

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-Gel
Description: Manufacturer: Ursapharm, Saarbrücken, Germany
Study: NCT02186600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bone-loading exercises
Description: Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
Study: NCT01647555

Intervention type: DRUG
Intervention: Cetuximab
Description: First cycle: 400 mg/m2 Next cycles: 250 mg/m2

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Curative dose: 66 to 70 Gy
Study: NCT02893007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief family-centered care (BFCC) program
Description: The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
Study: NCT01504477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab and bortezomib
Description: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.
Study: NCT00299442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Triple P Behavioural Family Intervention
Description: 10-week self-help workbook and videos
Study: NCT04267705

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group will receive a cup of rice 7 days/week over a 12-week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black bean
Description: This group will receive a cup of black bean7 days/week over a 12-week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chickpea
Description: This group will receive a cup of chick pea 7 days/week over a 12-week period
Study: NCT01310231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT03971591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Guided Lifestyle Program Intervention
Description: The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Immediate Guided Lifestyle Program Intervention
Description: The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
Study: NCT00644670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Study: NCT00625651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dummy AMG 655 (to maintain blind)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified FOLFOX6
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
Study: NCT00450541

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Four questionnaires taking 15-20 minutes total to complete.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting about 30 minutes.
Study: NCT00222872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone-related Protein
Description: PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
Study: NCT02839889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for two weeks, followed by two week open-label period
Study: NCT03058575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary MACs
Description: All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No Intervention for 8 weeks
Study: NCT05624905

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous Coronary Intervention Procedure